Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects
2
조회
0
다운로드
9
인용
0
참고문헌
키워드
초록
Hepatocellular carcinoma (HCC) is usually accompanied by chronic liver damage, which sometimes influences the selection of HCC treatment. The Barcelona Clinic Liver Cancer (BCLC) staging system, which was first introduced in 1999, is the most commonly used worldwide. Although the intermediate-stage (BCLC stage B) includes the largest number and heterogeneous HCC patients, the recommended treatment option is transarterial chemoembolization (TACE) only. However, recent progress in radical treatments such as hepatic resection, liver transplantation, radiation therapy, and percutaneous therapy has made it possible to treat selected patients with BCLC stage B HCC. Radical treatments are expected to prolong survival time. To-date, TACE has also progressed. In addition to conventional TACE, balloon-occluded TACE and drug-eluting beads TACE are available. These new modalities of TACE will improve therapeutic efficacy and reduce adverse events. One of the most serious concerns of TACE is that repeated TACE reduces the treatment effect and induces liver function impairment. The decision on when TACE should be interrupted is complex. Many molecular targeted agents are now available, and immune checkpoint inhibitors will soon be available for HCC patients with Child- Pugh class A worldwide. Under these circumstances, in patients with TACE unsuitability, switching to molecular targeted agents before deterioration of liver function might improve the prognosis compared to repeated TACE. We should pay attention to stop TACE in TACE-unsuitable HCC patients as it can induce the deterioration of liver function.
Abstract
Hepatocellular carcinoma (HCC) is usually accompanied by chronic liver damage, which sometimes influences the selection of HCC treatment. The Barcelona Clinic Liver Cancer (BCLC) staging system, which was first introduced in 1999, is the most commonly used worldwide. Although the intermediate-stage (BCLC stage B) includes the largest number and heterogeneous HCC patients, the recommended treatment option is transarterial chemoembolization (TACE) only. However, recent progress in radical treatments such as hepatic resection, liver transplantation, radiation therapy, and percutaneous therapy has made it possible to treat selected patients with BCLC stage B HCC. Radical treatments are expected to prolong survival time. To-date, TACE has also progressed. In addition to conventional TACE, balloon-occluded TACE and drug-eluting beads TACE are available. These new modalities of TACE will improve therapeutic efficacy and reduce adverse events. One of the most serious concerns of TACE is that repeated TACE reduces the treatment effect and induces liver function impairment. The decision on when TACE should be interrupted is complex. Many molecular targeted agents are now available, and immune checkpoint inhibitors will soon be available for HCC patients with Child- Pugh class A worldwide. Under these circumstances, in patients with TACE unsuitability, switching to molecular targeted agents before deterioration of liver function might improve the prognosis compared to repeated TACE. We should pay attention to stop TACE in TACE-unsuitable HCC patients as it can induce the deterioration of liver function.
참고문헌 (57)
- Bray F, "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 68, pp.394~424 (2018)
- Villanueva A, "Hepatocellular carcinoma", N Engl J Med, 380, pp.1450~1462 (2019)
- Lozano R, "Global and regional mortality from 235 causes of death for 20age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010", Lancet, 380, pp.2095~2128 (2012)
- Yin L, "Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan criteria: a RCT", J Hepatol, 61, pp.82~88 (2014)
- Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
- Finn RS, "Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma", N Engl J Med, 382, pp.1894~1905 (2020)
- Llovet JM, "Prognosis of hepatocellular carcinoma: the BCLC staging classification", Semin Liver Dis, 19, pp.329~338 (1999)
- Forner A, "Hepatocellular carcinoma", Lancet, 391, pp.1301~1314 (2018)
- Bolondi L, "Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions", Semin Liver Dis, 32, pp.348~359 (2012)
- Kudo M, "Subclassification of BCLC B stage hepatocellular carcinoma and treatment strategies: proposal of modified Bolondi’s subclassification (Kinki Criteria)", Dig Dis, 33, pp.751~758 (2015)
- Ciria R, "Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: modern surgical resection as a feasible alternative to transarterial chemoemolization", Eur J Surg Oncol, 41, pp.1153~1161 (2015)
- Hyun MH, "Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: a meta-analysis of highquality studies", Hepatology, 68, pp.977~993 (2018)
- Degroote H, "Extended criteria for liver transplantation in hepatocellular carcinoma. A retrospective, multicentric validation study in Belgium", Surg Oncol, 33, pp.231~238 (2020)
- Lingiah VA, "Liver transplantation beyond Milan criteria", J Clin Transl Hepatol, 8, pp.69~75 (2020)
- Yao FY, "Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging", Am J Transplant, 7, pp.2587~2596 (2007)
- Ho EY, "Expanded use of aggressive therapies improves survival in early and intermediate hepatocellular carcinoma", HPB (Oxford), 16, pp.758~767 (2014)
- Farinati F, "BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group", Liver Int, 35, pp.223~231 (2015)
- Dobrzycka M, "Stereotactic body radiation therapy for early-stage hepatocellular carcinoma - a systematic review on outcome", Acta Oncol, 58, pp.1706~1713 (2019)
- Mazzaferro V, "Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis", N Engl J Med, 334, pp.693~699 (1996)
- Yang JF, "Is stereotactic body radiotherapy better than radiofrequency ablation for the treatment of hepatocellular carcinoma?", J Clin Oncol, 34, pp.2797~ (2016)
- Kim N, "Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma", J Hepatol, 73, pp.121~129 (2020)
- Sangro B, "Radioembolization for hepatocellular carcinoma", J Hepatol, 56, pp.464~473 (2012)
- Salam R, "Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes", Gastroenterology, 138, pp.52~64 (2010)
- Vilgrain V, "Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial", Lancet Oncol, 18, pp.1624~1636 (2017)
- Chow PKH, "SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma", J Clin Oncol, 36, pp.1913~1921 (2018)
- Chen LT, "Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with intermediate and advanced", relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO, 2020, pp.31, 334~351
- Yamada R, "Hepatic artery embolization in 120 patients with unresectable hepatoma", Radiology, 148, pp.397~401 (1983)
- Verslype C, "Hepatocellular carcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up", Ann Oncol, 23(Suppl 7), pp.vi41~vii48 (2012)
- Llovet JM, "Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial", Lancet, 359, pp.1734~1739 (2002)
- Llovet JM, "Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival", Hepatology, 37, pp.429~442 (2003)
- Takayasu K, "Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines", J Hepatol, 56, pp.886~892 (2012)
- Forner A, "Treatment of intermediatestage hepatocellular carcinoma", Nat Rev Clin Oncol, 11, pp.525~535 (2014)
- European Association For The Study Of The Liver, "EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma", J Hepatol, 56, pp.908~943 (2012)
- Raoul JL, "Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization", Cancer Treat Rev, 37, pp.212~220 (2011)
- Vincenzi B, "Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: a literature-based metaanalysis", PLoS One, 10, pp.e0133488~ (2015)
- Irie T, "Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization: measurement of balloon-occluded arterial stump pressure", Cardiovasc Intervent Radiol, 36, pp.706~713 (2013)
- Irie T, "Selective balloonoccluded transarterial chemoembolization for patients with one or two hepatocellular carcinoma nodules: retrospective comparison with conventional super-selective TACE", Hepatol Res, 46, pp.209~214 (2016)
- Shirono T, "Epirubicin is more effective than miriplatin in balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma", Oncology, 96, pp.79~86 (2019)
- Golfieri R, "Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma", Br J Cancer, 111, pp.255~264 (2014)
- Lammer J, "Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study", Cardiovasc Intervent Radiol, 33, pp.41~52 (2010)
- Facciorusso A, "Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: current state of the art", World J Gastroenterol, 24, pp.161~169 (2018)
- Shimose S, "Increased arterio-portal shunt formation after drug-eluting beads TACE for hepatocellular carcinoma", Oncology, 98, pp.558~565 (2020)
- Kudo M, "Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 noninferiority trial", Lancet, 391, pp.1163~1173 (2018)
- Bruix J, "Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial", J Hepatol, 57, pp.821~829 (2012)
- Bruix j, "American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update", Hepatology, 53, pp.1020~1022 (2011)
- Sieghart W, "The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma", Hepatology, 57, pp.2261~2273 (2013)
- Hucke F, "The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE", J Hepatol, 60, pp.118~126 (2014)
- Kudo M, "Transarterial chemoembolization failure", refractoriness : JSHLCSGJ criteria 2014 update, 2014, pp.87(Suppl 1), 22~31
- Kudo M, "A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: Asia-Pacific primary liver cancer expert consensus statements", Liver Cancer, 9, pp.245~260 (2020)
- Shimose S, "Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: a multicenter cohort study using data mining analysis", Oncol Lett, 20, pp.2257~2265 (2020)
- Shimose S, "Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma", Oncol Lett, 19, pp.2667~2676 (2020)
- Chouaib S, "Hypoxia promotes tumor growth in linking angiogenesis to immune escape", Front Immunol, 3, pp.21~ (2012)
- Johnson PJ, "Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade", J Clin Oncol, 33, pp.550~558 (2015)
- Hiraoka A, "Albumin-bilirubin (ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan society of hepatology: a comparison with the liver damage and Child-Pugh classifications", Liver Cancer, 6, pp.204~215 (2017)
- Zehir A, "Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients", Nat Med, 23, pp.703~713 (2017)
- Sia D, "Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features", Gastroenterology, 153, pp.812~826 (2017)
- Harding JJ, "Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies", Clin Cancer Res, 25, pp.2116~2126 (2019)